Respiratory viral infections can be a cause of significant illness, particularly in vulnerable individuals as seen in the COVID-19 pandemic. An underactive or overactive immune response can lead to ineffective resolution of inflammation after an infection, especially in people with airway diseases such as asthma. A better understanding of immune responses to infection that does not rely on cell or animal models is crucial to help develop better treatments for lung inflammation.
An established method of studying inflammation in humans is through careful and controlled exposure (or "challenge") with a mimic of a virus to simulate an infection in a similar manner to that of a virus, but with the advantage of not causing an infection. The investigators have already developed a well-tolerated mimic of human viral infection using a sterile substance called Resiquimod (or R848). Since it does not contain living organisms there is no possibility of being infected. This has been used previously as a nasal spray to cause a mild short-lived inflammation that mimics a mild cold. This has been used safely in a range of people of different ages including those who have asthma.
There are differences however in how the nose and lungs respond to viral infections. This is particularly true in those with airway diseases such as asthma, who have cells in the airways of their lungs that respond in a different way to inflammatory triggers (such as viruses).
The current study aims to build on previous research by developing a new approach of studying inflammation in the lungs using a small volume of Resiquimod. This will be done by gently inhaling a fine mist through a mouthpiece into the lungs. Blood and phlegm samples would then be collected to assess inflammation and how well people tolerate the procedure.

Start Date24 May 2024

Sponsor / Collaborator

Cambridge University Hospitals NHS Foundation Trust

[+1]

NCT05710848 / RecruitingPhase 1/2

A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.

Start Date11 Jul 2023

Sponsor / Collaborator

Surge Therapeutics IncStartup

100 Clinical Results associated with Resiquimod

100 Translational Medicine associated with Resiquimod

100 Patents (Medical) associated with Resiquimod

936

Literatures (Medical) associated with Resiquimod

01 Jan 2025·Theriogenology

Expression of TLR7/8 in canine sperm and evaluation of the effect of ligand R848 on the sorting of canine X/Y sperm

Article

Author: Song, Mingqiang ; Xu, Shu ; Zhang, Wencai ; Zhao, Jianli ; Pan, Caixia ; Zhao, Yu

The aim of this study was to analyze the expression pattern of Toll receptor 7/8 (TLR7/8) in canine sperm, and explore the feasibility of using TLR7/8 ligand resiquimod(R848)to separate canine X and Y sperm. In this study, cellular immunofluorescence was used to analyze the expression of TLR7/8 in canine sperm, real-time fluorescence quantitative PCR was used to calculate the proportion of X sperm in the lower layer of the incubation solution with R848 to evaluate the sorting effect of R848 on canine X/Y sperm, and sperm quality detection system was used to analyze the effect of R848 on the motility of canine sperm. The mechanism of effect of R848 on canine sperm motility was analyzed by Western blot. The results showed that TLR8 was not expressed in all canine sperm, while TLR7 was expressed in all canine sperm and was localized in the head and tail of sperm. When 0.4 μM R848 was incubated with canine sperm for 1 h, the total motility, average path velocity (VAP), average straight-line velocity (VSL), and average curved-line velocity (VCL) of canine sperm were significantly decreased(P < 0.05). There was no significant difference between the lower and upper layers of the R848 treatment group and the control group(P > 0.05), and the proportion of X sperm was nearly half. The levels of NF-κB and GSK3α/β phosphorylation of sperm in R848 treatment group were significantly increased compared with control group(P < 0.05). The above results showed that TLR7/8 was not differentially expressed in canine X and Y sperm. R848 could decrease the motility of canine spermatozoa and inhibit sperm motility by the GSK3α/β-hexokinase pathway through the phosphorylation of NFκB and GSK3α/β, while could not separate X and Y spermatozoa. The method of sorting X/Y sperm based on TLR7/8 is not feasible for dogs.

31 Dec 2024·OncoImmunology

Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer

Article

Author: Rudaz, Serge ; Voegel, Clarissa D ; Alvarez, Montserrat ; Visconti, Gioele ; Nowak-Sliwinska, Patrycja ; Arnoux, Grégoire ; Tille, Jean-Christophe ; Tachet, Jérémie ; Pommier, Aurélien ; Moore, Jonathan ; Poinot, Hélène ; Olesti, Eulalia ; Bourquin, Carole ; González-Ruiz, Víctor ; Ezzar, Ounss ; Dupuychaffray, Eloïse ; Bejuy, Olivia

Although immune-based therapies have revolutionized the management of cancer, novel approaches are urgently needed to improve their outcome. We investigated the role of endogenous steroids in the resistance to cancer immunotherapy, as these have strong immunomodulatory functions. Using a publicly available database, we found that the intratumoral expression of 11 beta-hydroxysteroid dehydrogenase type 1 (HSD11B1), which regenerates inactive glucocorticoids into active glucocorticoids, was associated with poor clinical outcome and correlated with immunosuppressive gene signatures in patients with renal cell carcinoma (RCC). HSD11B1 was mainly expressed in tumor-infiltrating immune myeloid cells as seen by immunohistochemistry in RCC patient samples. Using peripheral blood mononuclear cells from healthy donors or immune cells isolated from the tumor of RCC patients, we showed that the pharmacological inhibition of HSD11B1 improved the response to the immune checkpoint inhibitor anti-PD-1. In a subcutaneous mouse model of renal cancer, the combination of an HSD11B1 inhibitor with anti-PD-1 treatment increased the proportion of tumor-infiltrating dendritic cells. In an intrarenal mouse tumor model, HSD11B1 inhibition increased the survival of mice treated with anti-PD-1. In addition, inhibition of HSD11B1 sensitized renal tumors in mice to immunotherapy with resiquimod, a Toll-like receptor 7 agonist. Mechanistically, we demonstrated that HSD11B1 inhibition combined with resiquimod increased T cell-mediated cytotoxicity to tumor cells by stimulating the antigen-presenting capacity of dendritic cells. In conclusion, these results support the use of HSD11B1 inhibitors to improve the outcome of immunotherapy in renal cancer and highlight the role of the endogenous glucocorticoid metabolism in the efficacy of immunotherapy.

01 Dec 2024·Biomaterials

Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy

Article

Author: Shi, Huiping ; Hu, Bo ; Tian, Yunxin ; Xu, Lin ; Yang, Jun ; Huang, Yuanyu ; Li, Jianan ; Jiang, Shaoping ; Ruan, Shaobo ; Ran, Guangyao ; Zhang, Yuquan ; Li, Zhaohan

The resistance of glioblastoma multiforme (GBM) to standard chemotherapy is primarily attributed to the existence of tumor-associated macrophages (TAMs) in the GBM microenvironment, particularly the anti-inflammatory M2 phenotype. Targeted modulation of M2-TAMs is emerging as a promising strategy to enhance chemotherapeutic efficacy. However, combination TAM-targeted therapy with chemotherapy faces substantial challenges, notably in terms of delivery efficiency and targeting specificity. In this study, we designed a pH-responsive hierarchical brain-targeting micelleplex loaded with temozolomide (TMZ) and resiquimod (R848) for combination chemo-immunotherapy against GBM. This delivery system, termed PCPA&PPM@TR, features a primary Angiopep-2 decoration on the outer layer via a pH-cleavable linker and a secondary mannose analogue (MAN) on the middle layer. This pH-responsive hierarchical targeting strategy enables effective BBB permeability while simultaneous GBM- and TAMs-targeting delivery. GBM-targeted delivery of TMZ induces alkylation and triggers an anti-GBM immune response. Concurrently, TAM-targeted delivery of R848 reprograms their phenotype from M2 to pro-inflammatory M1, thereby diminishing GBM resistance to TMZ and amplifying the immune response. In vivo studies demonstrated that targeted modulation of TAMs using PCPA&PPM@TR significantly enhanced anti-GBM efficacy. In summary, this study proposes a promising brain-targeting delivery system for the targeted modulation of TAMs to combat GBM.

News (Medical) associated with Resiquimod

20 Jul 2023

·www.outsourcing-pharma.com

US startup bags $32 million to blend cancer surgery and immunotherapy

The funding round was led by Bioluminescence Ventures. Other investors that participated include new investors KdT Ventures, Piedmont Capital and returning backers such as 8VC, Alumni Ventures and Camford Capita. Surge will use the cash infusion to expand its team and progress multiple clinical trials of its cancer immunotherapies, including its lead candidate STM-416. Surgery is a standard of care for many solid tumors. However, many cancers can relapse within several years of surgery, in part because the procedure can suppress the immune system and help tumor cells to hide from immune cells. To overcome this challenge, STM-416 is a biodegradable hydrogel-based treatment that is injected at the surgical site during the operation. Once in place, the hydrogel slowly releases resiquimod, a small molecule drug that activates a protein called toll-like receptor (TLR) on immune cells, to enhance the immune system response against the cancer. By delivering STM-416 during surgery, the immunotherapy dose is focused on the tumor site and is designed to prevent relapse. Surge recently dosed the first patients in a phase 1/2a trial for the prevention of recurrence and/or progression of non-muscle invasive bladder cancer (NMIBC) after surgery to remove the tumor. “The capital that we have raised to date will allow SURGE to generate proof-of-concept event-free survival data with our lead program and advance our second and third programs through phase 1,” said Michael Goldberg, CEO and founder of Surge, in a public release. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Surge was founded in 2016 based on Goldberg’s work at Harvard Medical School. The company raised a $26 million Series A financing round in October 2022 to fund the development of its technology and to launch its first two clinical programs. “Currently, cancer surgery is a physical intervention only,” stated Kouki Harasaki, managing partner at Bioluminescence Ventures, in the public release. “Physicians typically do not administer any kind of immunotherapy during surgical tumor resection, which we believe is a missed opportunity, as post-surgical recurrence and metastasis account for 90 percent of cancer-related deaths.” “Surge has a unique first-mover advantage in the intraoperative immunotherapy space to potentially improve patient outcomes and become the standard of care as a seamless complement to surgery.” Few companies at present are developing immunotherapy approaches combined with cancer surgery. One research group at the University of Pennsylvania tested an approach in mouse models where they surgically removed part of a tumor and placed a human CAR-T cell immunotherapy in the wound. According to findings published in January 2023, the CAR-T cells were able to destroy the remaining tumor cells.

Immunotherapy

19 Jul 2023

·www.biospace.com

SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery

- Funding will be used to advance clinical development of the SURGE™ intraoperative immunotherapy programs - Company doses first two patients in Phase 1/2a study for lead intraoperative immunotherapy candidate, STM-416, in patients with recurrent bladder cancer CAMBRIDGE, Mass.--(BUSINESS WIRE)-- SURGE Therapeutics (SURGE), a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced today the completion of a $32 million Series B financing led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech. The funding will be used to further development of the SURGE™ intraoperative immunotherapy approach, expand the team, and advance multiple clinical trials for its injectable biodegradable hydrogel, which may be administered during any surgical oncology procedure. In connection with the financing, Kouki Harasaki, Ph.D., Managing Partner at Bioluminescence Ventures, will join SURGE’s Board of Directors. The company recently dosed the first two patients in a Phase 1/2a trial for its lead intraoperative immunotherapy candidate, STM-416, in patients with recurrent bladder cancer – a major unmet medical need – to improve post-resection outcomes. SURGE’s intraoperative approach enables extended, localized release of immunotherapy at the site of surgical tumor resection. This intervention may prevent tumor relapse and induce systemic antitumor immunity, potentially eliminating existing micrometastases. “The capital that we have raised to date will allow SURGE to generate proof-of-concept event-free survival data with our lead program and advance our second and third programs through Phase 1,” said Michael Goldberg, Ph.D., CEO & Founder, SURGE Therapeutics. “Intraoperative immunotherapy is a platform approach that can potentially confer clinical benefit across multiple cancer types, using different molecules. Surgery is the standard of care for most patients with solid tumors, and it is common for a small number of cancer cells to remain behind. Our mission is to ensure that nobody grieves the loss of a loved one due to preventable post-surgical cancer recurrence.” “Currently, cancer surgery is a physical intervention only. Physicians typically do not administer any kind of immunotherapy during surgical tumor resection, which we believe is a missed opportunity, as post-surgical recurrence and metastasis account for 90 percent of cancer-related deaths,” said Kouki Harasaki, Ph.D., Managing Partner, Bioluminescence Ventures. “SURGE has a unique first-mover advantage in the intraoperative immunotherapy space to potentially improve patient outcomes and become the standard of care as a seamless complement to surgery. We are very excited about working with the SURGE team towards realizing this objective.” Reprogramming the body’s response to surgery from immunosuppressive to immunostimulatory may trigger the patient’s immune system to destroy both local and distal residual cancer cells, reducing recurrence and improving survival. In multiple aggressive murine models of metastasizing cancer, intraoperative immunotherapy vastly improved survival benefit relative to traditional routes of administration, whether systemic or local. Confirmation in patients could represent a major advancement in cancer care. About SURGE Therapeutics SURGE Therapeutics (The Intraoperative Immunotherapy Company™) seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed. The SURGERx™ platform is designed to improve the efficacy and safety of immunotherapy treatment, concentrating the effective dose where and when it may yield tremendous impact. SURGE is based in Cambridge, MA. For more information, visit and follow us on LinkedIn. SURGE, SURGE Therapeutics, SURGERx, and The Intraoperative Immunotherapy Company are trademarks of SURGE Therapeutics, Inc.

ImmunotherapyClinical Study

31 May 2023

·www.globenewswire.com

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

– TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells – TransCon IL-2 β/γ administered every 3 weeks was generally well tolerated, with no meaningful effect on Tregs and eosinophils. – At the TransCon IL-2 β/γ recommended Phase 2 dose (RP2D), no dose limiting toxicity (DLT), vascular leak syndrome, or grade 3/4 cytokine release syndrome observed – Further follow-up for the TransCon TLR7/8 Agonist monotherapy cohort showed additional abscopal responses – Webcast of Ascendis’ Oncology Program Update to begin at 10:00 am ET COPENHAGEN, Denmark, May 31, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) will today host an investor meeting highlighting the latest developments in the Company’s Oncology programs, including clinical data updates and a review of clinical development strategy for the Company’s two immuno-oncology product candidates, TransCon TLR7/8 Agonist and TransCon IL-2 β/γ. Both are designed to recruit innate and adaptive components of the immune system to maximize anti-cancer activity while reducing dose-limiting toxicities. “TransCon IL-2 β/γ was designed by applying the TransCon technology together with protein bioscience to solve problems with aldesleukin that have eluded industry for many decades - to create a well-tolerated IL-2 therapy that has the potential to effectively activate the immune system to drive anti-cancer activity without dosing complexity that limits aldesleukin use. Today we are reporting for the first-time clinical data supporting the successful design for TransCon IL-2 β/γ,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO. “We are excited to highlight the progress we have made across our two immuno-oncology product candidate programs, TransCon IL-2 β/γ and TransCon TLR7/8 Agonist,” said Stina Singel, M.D., Ph.D., Executive Vice President, Head of Clinical Development, Oncology at Ascendis Pharma. “The clinical data shared today from both programs showed an acceptable safety profile and single-agent clinical activity. Data from indication-specific cohorts, including melanoma, head-and-neck, and non-small cell lung cancer are expected in 2024.” Today’s meeting highlights include: TransCon IL-2 β/γ program update from the Phase 1/2 IL-Believe Trial Phase 1 monotherapy dose escalation complete; 25 heavily pre-treated patients enrolled (median of 4 prior lines of systemic therapies).120 µg/kg IV every three weeks selected as monotherapy recommended Phase 2 dose (RP2D).Eight monotherapy patients dosed at RP2D; of the three efficacy evaluable patients to date, one partial response in a metastatic colorectal cancer patient, and one stable disease in a renal cell carcinoma patient (data cut April 28, 2023).At RP2D, TransCon IL-2 β/γ was generally well-tolerated with no DLT observed, no vascular leak syndrome and no grade 3 or 4 cytokine release syndrome.As designed, the non-alpha TransCon IL-2 β/γ expanded local and systemic cytotoxic immune effector cells (CD8+ T and NK cells) without clear effect on Tregs and eosinophils.RP2D for combination therapy with checkpoint inhibitor dose escalation data expected in the third quarter of 2023 and will be presented at a scientific congress in the fourth quarter.Enrollment continues in indication-specific cohorts for the Phase 2 portion of the IL-Believe trial. TransCon TLR7/8 Agonist program update from the Phase 1/2 transcendIT-101 Trial Additional follow-up indicates further clinical activity in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab. Results supporting selection of RP2D from transcendIT-101 were first reported at SITC 2022 last November.Preliminary results showed that TransCon TLR7/8 Agonist was well-tolerated both as a monotherapy and in combination with pembrolizumab.Enrollment continues in the Phase 2 portion of transcendIT-101 at the RP2D of 0.5 mg/lesion for up to two lesions, which is being evaluated in four indication-specific cohorts. TransCon IL-2 β/γ is an investigational long-acting prodrug with sustained release of an IL-2Rβ/γ-selective analog (IL-2 β/γ) designed to address the known limitations of interleukin-2 (IL-2) cancer immunotherapy through prolonged activation of IL-2Rβ/γ with low Cmax. TransCon TLR7/8 Agonist is an investigational long-acting prodrug designed to provide sustained, localized release over weeks of resiquimod (a potent immune response modifier with clinically demonstrated anti-tumor activity) with low systemic exposure. Oncology Program Update Meeting Webcast InformationAscendis’ 2023 Oncology Program Update Meeting will take place today starting at 10:00 am Eastern Time (ET). Those who would like to participate may access the live webcast here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of our website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Germany (Heidelberg, Berlin and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). Visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to create well-tolerated immune-oncology product candidates without dosing complexity that limits use of current therapies; (ii) the timing of data from indication-specific cohorts for TransCon IL-2 β/γ and TransCon TLR7/8 Agonist; (iii) the timing of dose escalation combination therapy data from the Phase 1/2 IL-Believe trial and its presentation at a scientific congress; (iv) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated, global biopharma company, and (v) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in its development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on its business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © May 2023 Ascendis Pharma A/S. Investor Contacts:Tim LeeAscendis Pharma+1 (650) 374-6343tle@ascendispharma.comir@ascendispharma.com Media Contact:Melinda BakerAscendis Pharma+1 (650) 709-8875media@ascendispharma.com Patti BankICR Westwicke+1 (415) 513-1284patti.bank@westwicke.com

Phase 1ImmunotherapyClinical Result

100 Deals associated with Resiquimod

External Link

KEGG	Wiki	ATC	Drug Bank
-	Resiquimod	-	DB06530

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	Phase 2	US	Surge Therapeutics IncStartup	11 Jul 2023
Recurrent Bladder Cancer	Phase 2	US	Surge Therapeutics IncStartup	11 Jul 2023
Cutaneous T-Cell Lymphoma	Phase 2	DE	Galderma Research & Development SNC	19 Dec 2017
Cutaneous T-Cell Lymphoma	Phase 2	US	Galderma Research & Development SNC	19 Dec 2017
Actinic Keratosis	Phase 2	-	3M Health Care, Inc.	-
Basal Cell Carcinoma	Phase 2	-	Galderma International SAS	-
Basal Cell Carcinoma	Phase 2	-	3M Health Care, Inc.	-
Hepatitis B	Phase 2	-	3M Health Care, Inc.	-
Hepatitis B	Phase 2	-	Galderma International SAS	-
Cutaneous T-Cell Lymphoma	Discovery	FR	Galderma Research & Development SNC	19 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00960752 (CTgov)	Phase 2	Melanoma	47	MAGE-3+gp100+R848 gel (Group 1: GP100 and MAGE-3 + R848)	amjzefnjgf(frgygsovva) = vhywrsbvqq bqrqqptwfn (wuhvhaibmt, dpwhmvwxjb - krfvjesssx) View more	-	13 Aug 2021
				MAGE-3+gp100 (Group 2: GP100 and MAGE-3)	amjzefnjgf(frgygsovva) = rbfzyfznkm bqrqqptwfn (wuhvhaibmt, diplfewpvp - grgzxbusob) View more
NCT01808950 (CTgov)	Phase 1/2	Basal Cell Carcinoma	4	0.06% Resiquimod Gel - A (0.06% Resiquimod Gel - A)	swlrdhimld(jzpsckghqe) = bjmmezvylk bogliwfdnf (teqlhwqhas, vilrlupsgc - ufblkxqasa) View more	-	22 Jun 2016
				0.06% Resiquimod Gel - B (0.06% Resiquimod Gel - B)	swlrdhimld(jzpsckghqe) = muxdbzknhj bogliwfdnf (teqlhwqhas, frqxrehxoq - dqkwyzemhr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis